Arginine Deiminase Enzyme Evolving as a Potential Antitumor Agent

Title:Arginine Deiminase Enzyme Evolving as a Potential Antitumor Agent

Volume: 18 Issue: 4

Author(s): Rakesh Ravindra Somani*Pratip Kashinath Chaskar

Affiliation:

• Department of Pharmaceutical Chemistry, Vivekanand Education Society's College of Pharmacy, Chembur (E), Mumbai - 400 074, Maharashtra,India

Keywords: Arginine, Arginine deiminase (ADI), Arginosuccinate synthetase (ASS), Arginosuccinate lyase (ASL), Hepatocellular carcinoma, malignant melanoma.

Abstract: Some melanomas and hepatocellular carcinomas have been shown to be auxotrophic for arginine. Arginine deiminase (ADI), an arginine degrading enzyme isolated from Mycoplasma, can inhibit the growth of these tumors. It is a catabolizing enzyme which catabolizes arginine to Citrulline. Tumor cells do not express an enzyme called arginosuccinate synthetase (ASS) and hence, these cells become auxotrophic for arginine. It is found that ADI is specific for arginine and did not degrade other amino acid. This review covers various aspects of ADIs like origin, properties and chemical modifications for better antitumor activity.

Cite this article as:

Somani Ravindra Rakesh*, Chaskar Kashinath Pratip, Arginine Deiminase Enzyme Evolving as a Potential Antitumor Agent, Mini-Reviews in Medicinal Chemistry 2018; 18(4) . https://dx.doi.org/10.2174/1389557516666160817102701